Testing a new skin treatment for moderate-to-severe eczema in teens and adults

Plain-English translation of NCT07690371 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing a new medication called to see if it can help people with moderate-to-severe eczema (atopic dermatitis) that hasn't responded well to creams and other treatments. The study will compare this medication to placebo (a dummy treatment with no active drug) to find out if the medication actually works and is safe. About 510 people will participate over roughly 15 months.

Many people with moderate-to-severe eczema don't get enough relief from topical creams and lotions alone, and they need stronger treatment options. This trial is testing whether this new medication could be a safe and effective choice for patients who haven't had success with existing treatments.

Do you qualify?

You likely qualify if…

you are at least 12 years old and weigh at least 88 pounds
you have been diagnosed with eczema for at least 12 months
your eczema affects at least 10% of your skin and is moderate-to-severe based on clinical scores
you have tried topical creams or lotions within the past 6 months without adequate improvement, or you had a reaction to them
you are willing to use effective contraception if you can become pregnant

You likely don't qualify if…

you have other active skin conditions besides eczema, or a skin infection in your eczema-affected areas that needs systemic antibiotics
your eczema has been unstable or unpredictable in the past
you have a history of chronic hives or hives within the past 4 weeks
you have received certain prior treatments for eczema or other conditions, including biologic drugs, JAK inhibitors, or previous experimental agents
you currently have an active infection or have had one recently

What participation looks like

If you enroll, you'll receive the medication or placebo as an injection every 2 weeks for the first part of the study (the induction phase), then less frequently during the maintenance phase. You'll have regular clinic visits where the research team will check on your eczema, ask how you're doing, and monitor for any side effects. The entire study lasts about 15 months, and some participants may be switched to open-label treatment (where everyone knows they're receiving the active medication) if they're not improving.

AI-generated summary from trial data · Jul 9, 2026 · Not medical advice

Trial locations(1 site)

United States

Nektar Investigative Site, St. Petersburg, Florida